Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 8/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20507899 | 0.90 | WNT3A (0.48) | WNT3ARAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL20508020 | 0.90 | WNT3A (0.49) | WNT3ARAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL18974100 | 0.90 | RAB9A (0.58) | WNT3ARAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL20508213 | 0.89 | WNT3A (0.56) | WNT3ARAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL23699256 | 0.88 | WNT3A (0.53) | WNT3ASMN1; SMN2TP53POLB | |
| SCHEMBL20508039 | 0.86 | SCD (0.47) | WNT3ARAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL20507995 | 0.84 | WNT3A (0.55) | WNT3AMAPK1PORCN | |
| SCHEMBL20508030 | 0.83 | WNT3A (0.56) | WNT3APORCN | |
| SCHEMBL20507964 | 0.82 | WNT3A (0.47) | WNT3ARAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL20508216 | 0.82 | WNT3A (0.57) | WNT3APORCN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388428-B1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) | 2021-08-04 | — | — | EP | claimed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | claimed |
| US-20180271846-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2018-09-27 | — | — | US | claimed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | disclosed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | disclosed |
| US-20180271846-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2018-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271846-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | WNT1, WNT3, WNT3A | WNT3A 3/4885RAB9A 810/4885SMN1; SMN2 4801/4885 |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | WNT1, WNT3, WNT3A | WNT3A 3/4885RAB9A 613/4885SMN1; SMN2 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.